Supplementary Figure 1 from Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function

Autor: Carlos L. Arteaga, Rebecca S. Cook, María Gabriela Kuba, Cammie R. Sutton, Joan T. Garrett

PDF file - 110K, Dose responsiveness of U3-1287 to downregulation of HER3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bfd02973f2fe8f21cc0320a1f3e5129
https://doi.org/10.1158/1078-0432.22451955

Supplementary Figure 1 from Trastuzumab-Resistant Cells Rely on a HER2-PI3K-FoxO-Survivin Axis and Are Sensitive to PI3K Inhibitors

Autor: Carlos L. Arteaga, Jenny C. Chang, Bhuvanesh Dave, María Gabriela Kuba, Ritwik Ghosh, Cammie Sutton, Neil E. Bhola, Anindita Chakrabarty

PDF file - 125K, Inhibition of trastuzumab-resistant cells by RNAi of p110 alpha and beta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46356211020b290b4d7b295ce8cd0627
https://doi.org/10.1158/0008-5472.22398005.v1

Supplementary Figure 4 from Trastuzumab-Resistant Cells Rely on a HER2-PI3K-FoxO-Survivin Axis and Are Sensitive to PI3K Inhibitors

Autor: Carlos L. Arteaga, Jenny C. Chang, Bhuvanesh Dave, María Gabriela Kuba, Ritwik Ghosh, Cammie Sutton, Neil E. Bhola, Anindita Chakrabarty

PDF file - 135K, Inhibition of trastuzumab-resistant cells by RNAi or pharmacological inhibition of survivin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5945a26b2313bcd73eed4923261cfcbf
https://doi.org/10.1158/0008-5472.22397996.v1

Supplementary Figure 5 from Trastuzumab-Resistant Cells Rely on a HER2-PI3K-FoxO-Survivin Axis and Are Sensitive to PI3K Inhibitors

Autor: Carlos L. Arteaga, Jenny C. Chang, Bhuvanesh Dave, María Gabriela Kuba, Ritwik Ghosh, Cammie Sutton, Neil E. Bhola, Anindita Chakrabarty

PDF file - 162K, Inhibition of survivin and IL8 expression by short-term treatment with XL147 + trastuzumab in HCC1954 xenografts

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09d1b9e53a28201c669354e4fca754cf
https://doi.org/10.1158/0008-5472.22397993

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Autor: Mayer IA; Ingrid A. Mayer, Vandana G. Abramson, Justin M. Balko, María Gabriela Kuba, Melinda E. Sanders, and Carlos L. Arteaga, Vanderbilt University, Nashville, TN; Steven J. Isakoff, Massachusetts General Hospital, Boston, MA; Andres Forero, University of Alabama, Birmingham, AL; Jeffrey T. Yap, Huntsman Cancer Institute, Salt Lake City, UT; Annick D. Van den Abbeele and Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Yisheng Li, MD Anderson Cancer Center, Houston, TX; and Lewis C. Cantley, Weill Cornell Medical College, New York, NY., Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2014 Apr 20; Vol. 32 (12), pp. 1202-9. Date of Electronic Publication: 2014 Mar 24.